Results 21 to 30 of about 957 (170)

In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance [PDF]

Journal of Global Antimicrobial Resistance, 2022
Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health care settings as a frequent cause of serious infections with limited treatment options. This study evaluated the in vitro activity of sulbactam (SUL) combined with durlobactam (DUR) against a ...
Findlay, J., Poirel, L., Bouvier, M., Nordmann, P.   +3 more
openaire   +4 more sources

Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii–Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Canadian Journal of Infectious Diseases and Medical Microbiology
Summary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with ...
Wissam K. Kabbara, Elina Sadek, Hanine Mansour   +2 more
doaj   +2 more sources

The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections

Current Opinion in Infectious Diseases
Purpose of review Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles.
Bassetti, Matteo, Giacobbe, Daniele Roberto, Castaldo, Nadia, Vena, Antonio   +3 more
openaire   +4 more sources

Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance in Pseudomonas aeruginosa [PDF]

Antimicrobial Agents and Chemotherapy
The triple action of the diazabicyclooctane (DBO) zidebactam (antibacterial activity [penicillin-binding protein 2 {PBP2} inhibitor], β-lactam enhancement [synergy with PBP3 inhibitors], and β-lactamase inhibition [classes A and C]) provides a promising ...
Miquel Àngel Sastre-Femenia, Maria Antonia Gomis-Font, Almudena Fernández-Muñoz, Daniela Salazar-Londoño, Bartolome Moya, Antonio Oliver   +5 more
doaj   +2 more sources

Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam in Mycobacterium abscessus [PDF]

Antibiotics
Background: Infections caused by the multidrug-resistant pathogen Mycobacterium abscessus (Mab) are notoriously difficult to treat. The novel β-lactamase inhibitor durlobactam, in combination with β-lactams, shows potent bactericidal activity against Mab,
Dereje Abate Negatu, Wassihun Wedajo Aragaw, Min Xie, Véronique Dartois, Thomas Dick   +4 more
doaj   +2 more sources

Microbiological eradication of XDR Acinetobacter baumannii intra-abdominal infection using sulbactam-durobactam: clinical and microbiological outcomes amidst irreversible host comorbidities [PDF]

Frontiers in Medicine
BackgroundThe management of extensively drug-resistant (XDR) Acinetobacter baumannii (CRAB) in deep-seated infections remains a critical challenge, particularly when compounded by severe host comorbidities.Case presentationWe report the case of a 63-year-
Lei Yu, Jieli He, Waiming Chan, Waiming Chan, Shan Zou, Qingshan Zhou, Jun Jin   +6 more
doaj   +2 more sources

An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review

Health Science Reports
Purpose Infections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate.
Ayush Anand, Amogh Verma, Sarabjeet Kaur, Priyangi Kathayat, Rachel M. Manoj, Aakanksha Aakanksha, Justice K. Turzin, Prakasini Satapathy, Mahalaqua N. Khatib, Shilpa Gaidhane, Quazi S. Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Arihant Surana   +13 more
doaj   +2 more sources

Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants [PDF]

Antimicrobial Agents and Chemotherapy
The persistence of multidrug-resistant Acinetobacter baumannii remains a clinical challenge. Cefepime/enmetazobactam is a novel combination with demonstrated activity against extended-spectrum β-lactamase-producing Enterobacterales, but its activity ...
Gabriela-Alejandra Báez-Barroso, Arianna Rodríguez-Coello, Juan Carlos Vázquez-Ucha, Silvia López-Argüello, Michelle Outeda-García, Lucía González-Pinto, Andrea García-Pose, Paula Guijarro-Sánchez, Isaac Alonso-García, Emilio Lence, Concepción González-Bello, Antonio Oliver, Jorge Arca-Suárez, Bartolome Moya, Germán Bou, Alejandro Beceiro   +15 more
doaj   +2 more sources

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Frontiers in Medicine
Meningitis caused by Acinetobacter species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality.
Nicholas Mercuro
exaly   +3 more sources

Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report [PDF]

Frontiers in Pharmacology
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported.
Chunxi Fu, Chunxi Fu, Xue Tang, Xue Tang, Xia Guo, Xia Guo, Liang Huang, Liang Huang, Liang Huang, Ju Gao, Ju Gao, Rong Yang, Rong Yang   +12 more
doaj   +2 more sources